
Claims




1. Use of a compound of formula I:







I



or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, wherein:









X represents NH;

Y represents:  ,  ,  ,

 ,  ,

 ,  ,

 or, 

Z represents: , , , , , , , or ,


R^1 represents H, Cl, F, OCF_3, OCH_3 or NO_2;

R^2 represents H, Cl, or OCH_3;

R^3 represents H, F, CF_3, OCF_3, CH_3, OCH_3; CH_2CH_3, Cl, $-C(=O)OCH_3$ or NO_2;

R^4 represents H, Cl or CH_3;

R^5 represents H, Cl or F;


R^6 represents H, CF_3, NO_2, $N(CH_3)_2$, or ;




R^7 represents H or OH; and




R^8 represents H or CH_3;




wherein the dotted lines represent the point of attachment to the rest of the molecule;




provided that:




the compound is not ;




; ; ;




; ; ;




; ; ;




; ; ;




; ; ;




; ; ;




; ; ;


; ; ;




;

;

;




;

;

;








;

;

;


;

;
or 
;

the compound is not 
;


;

;


;

;


;

;

;

;

; ; or

;

at least one of R^1 to R^7 is not H;

the compound is not 1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylurea;

the compound is not 1-(4-chlorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea;

the compound is not 1-(3-fluorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea;

the compound is not 1-(3,4-dichlorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea;

the compound is not 1-(2,3-dichlorophenyl)-3-(6-methoxybenzo[d]thiazol-2-yl)urea;

the compound is not 1-(3-chlorophenyl)-3-(2-hydroxyphenyl)urea;

the compound is not 1-(4-chlorophenyl)-3-(2-hydroxyphenyl)urea;


the compound is not 1-(3-fluorophenyl)-3-(6-methoxy-1,3-benzothiazol-2-yl)urea;

the compound is not 1,3-bis(3-chlorophenyl)urea;


the compound is not 1-(3-chlorophenyl)-3-(4-methylphenyl)urea; and


the compound is not 1-(3-chlorophenyl)-3-(2,4-dichlorophenyl)urea.


2. Use according to Claim 1, wherein Z represents:




,




,


,



,




, or


, where the dotted lines represent the point of attachment to the rest of the molecule.

3. Use according to Claim 2, wherein Z represents



or


,
where the dotted lines represent the point of attachment to the rest of the molecule.

4. Use according to any one of the preceding claims wherein R^1 represents H, Cl, F, OCF_3, or OCH_3.

5. Use according to claim 4, wherein R^1 represents H, Cl, F, or OCH_3.

6. Use according to any one of the preceding claims wherein R^2 represents H, Cl, or OCH_3.

7. Use according to any one of the preceding claims wherein R^3 represents H, F, CF_3, CH_3, OCH_3, Cl, or NO_2.

8. Use according to Claim 7, wherein R^3 represents H, F, CF_3, CH_3, OCH_3, or Cl.

9. Use according to any one of the preceding claims wherein R^4 represents H or CH_3, optionally wherein R^4 represents H.

10. Use according to any one of the preceding claims wherein R^5 represents H or Cl, optionally wherein R^5 represents H.


11. Use according to any one of the preceding claims wherein R^6 represents H, CF_3, or NO_2.


12. Use according to Claim 11, wherein R^6 represents H or NO_2.


13. Use according to any one of the preceding claims wherein R^7 represents OH.


14. Use according to any one of the preceding claims wherein R^8 represents H.


15. Use according to any one of the preceding claims, wherein Y represents:




,



,



,


,


,




,


,



or ,


wherein the dotted lines represent the point of attachment to the rest of the molecule.


16. Use according to Claim 15, wherein Y represents:




,



,


,



,



or ,

wherein the dotted lines represent the point of attachment to the rest of the molecule.


17. Use according to any one of Claims 1 to 14, wherein Y represents:



, , or

where the dotted lines represent the point of attachment to the rest of the molecule.



18. Use according to Claim 17, wherein Y represents:
















or ,








where the dotted lines represent the point of attachment to the rest of the molecule.




19. Use of a compound having the formula:

Formula



Formula








Formula







Formula








Formula




or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer.

20. Use according to any one of the preceding claims, wherein the cancer is selected from liver cancer (e.g. hepatocellular carcinoma) and lung cancer.